【Helius Medical Technologies-Product PoNS】Helius Provides a Business Update on Clinical Experience to Date in Canada

Partner News

28th Aug 2019- Helius Medical Technologies, Inc. issued an announcement, which is summarized as follows:

Overall Clinical Results:

√  The first several mild -to-moderate TBI patients that have completed 14 weeks of treatment in Canada are consistent with what we saw in our two randomized clinical trials in mmTBI, one for 5 weeks and one for 14 weeks:

√  Patients in Canada are demonstrating the same pattern of positive change, with improvements in balance and gait within the first 2 weeks followed by continued improvement over their total 14 weeks of treatment

√  The majority of patients showed improvement in comfortable gait speed, a measure of their ability to walk, with a meaningful clinical difference at the end of treatment

√  Mean patient compliance is over 90%, which is also consistent with what we experienced in the clinical trials

√  Not all patients who used PoNS got better.

“While we are pleased with the clinical results to date it is important to note that PoNS treatment is not for everyone. We are extremely pleased to have provided hope and, in the majority of patients treated, to help them resume their activities of daily living that were impaired by their balance and gait disorder related to their mild-to-moderate TBI,” said company CEO Phil Deschamps.

The original website link:https://heliusmedical.com/index.php/newsroom/news-release/2019/289-